CDXC vs. ACB, MDWD, BTMD, FTLF, NAII, MTEX, MNMD, USNA, CGC, and CRON
Should you be buying ChromaDex stock or one of its competitors? The main competitors of ChromaDex include Aurora Cannabis (ACB), MediWound (MDWD), biote (BTMD), FitLife Brands (FTLF), Natural Alternatives International (NAII), Mannatech (MTEX), Mind Medicine (MindMed) (MNMD), USANA Health Sciences (USNA), Canopy Growth (CGC), and Cronos Group (CRON). These companies are all part of the "medicinals & botanicals" industry.
ChromaDex (NASDAQ:CDXC) and Aurora Cannabis (NASDAQ:ACB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, community ranking, dividends, analyst recommendations and institutional ownership.
15.4% of ChromaDex shares are held by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are held by institutional investors. 10.6% of ChromaDex shares are held by insiders. Comparatively, 0.0% of Aurora Cannabis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
ChromaDex received 151 more outperform votes than Aurora Cannabis when rated by MarketBeat users. Likewise, 63.94% of users gave ChromaDex an outperform vote while only 59.44% of users gave Aurora Cannabis an outperform vote.
ChromaDex has a net margin of -5.91% compared to Aurora Cannabis' net margin of -48.82%. ChromaDex's return on equity of -17.81% beat Aurora Cannabis' return on equity.
ChromaDex has higher earnings, but lower revenue than Aurora Cannabis. ChromaDex is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.
In the previous week, Aurora Cannabis had 2 more articles in the media than ChromaDex. MarketBeat recorded 7 mentions for Aurora Cannabis and 5 mentions for ChromaDex. ChromaDex's average media sentiment score of 0.88 beat Aurora Cannabis' score of 0.38 indicating that ChromaDex is being referred to more favorably in the media.
ChromaDex has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500.
ChromaDex currently has a consensus target price of $5.87, indicating a potential upside of 56.44%. Given ChromaDex's higher probable upside, equities research analysts clearly believe ChromaDex is more favorable than Aurora Cannabis.
Summary
ChromaDex beats Aurora Cannabis on 12 of the 16 factors compared between the two stocks.
Get ChromaDex News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDXC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CDXC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ChromaDex Competitors List
Related Companies and Tools
